Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00018850 · ClinicalTrials.gov registry record · NA
5HT3 Antagonism and Auditory Gating in Schizophrenia
A NA study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- NA
- Development phase
NCT00018850: Completed NA study, sponsored by US Department of Veterans Affairs.
NCT00018850 is a NA study that has completed, run by US Department of Veterans Affairs. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00018850, a NA study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The target groups in this study are brain waves and neurotransmitters (chemical messengers) in the brain. Subjects with diagnosed with schizophrenia will be studied. The study will help understand more about normal brain functioning and how that functioning differs in people with schizophrenia. Another purpose of this study is to determine how the altered brain functioning in schizophrenia contributes the symptoms found in the illness.
Interventions
- DRUG ondansetron
- DRUG nicotine
- DRUG haloperidol
- BEHAVIORAL neuropsychological testing
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-06 |
| Est. Completion | 2003-06 |
| Phase | NA |
What the finished NCT00018850 record still lists
NCT00018850 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which ondansetron is the first listed.
NCT00018850 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00018850 about?
NCT00018850 is a clinical study titled "5HT3 Antagonism and Auditory Gating in Schizophrenia". The target groups in this study are brain waves and neurotransmitters (chemical messengers) in the brain. Subjects with diagnosed with schizophrenia will be studied. The study will help understand more about normal brain functioning and how that functioning differs in people with schizophrenia. Anot...
What is the current status of trial NCT00018850?
This trial is currently completed. It is a NA study. The study started on 1998-06. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00018850?
The interventions under investigation include: ondansetron (DRUG), nicotine (DRUG), haloperidol (DRUG), neuropsychological testing (BEHAVIORAL).
Who is sponsoring clinical trial NCT00018850?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia